Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

Hepatology

Volumn 55, Issue 6, 2012, Pages 1692-1699

  Sun, Jin Hua ^a   O'Boyle II, Donald R ^a   Zhang, Yan ^a,c   Wang, Chunfu ^a   Nower, Peter ^a   Valera, Lourdes ^a   Roberts, Susan ^a   Nettles, Richard E ^b,d   Fridell, Robert A ^a   Gao, Min ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; NONSTRUCTURAL PROTEIN 5A;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REPLICON; VIRUS STRAIN;

ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; IMIDAZOLES; POLYMORPHISM, GENETIC; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84861546211     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25581     Document Type: Article

References (23)

1. World Health Organization. Viral cancers. Available at:. Accessed on July 1, 2009.
2. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2001; 20: 17-35.
3. Simmonds P. Viral heterogenecity of the hepatitis C virus. J Hepatol 1999; 31(SUPPL. 1): 54-60.
4. Strader DB, Wright T, Thomas L, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 1147-1171.
5. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, et al. Treatment of chronic hepatitis C: a systematic review. HEPATOLOGY 2006; 36: S135-S144.
6. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
7. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 28: 705-716.
8. Blight KJ, Kolyhalov AA, Reed KE, Agapov EV, Rice CM. Molecular virology of hepatitis C: an update with respect to potential antiviral targets. Antiviral Ther 1998; 3(SUPPL. 3): 71-81.
9. Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol 2005; 13: 2406-2415.
10. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Perelson AS. Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
11. Chevaliez S, Rodriguez C, Soulier A, Ahmed-Belkacem A, Hézode C, Pawlotsky J-M. Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations. Presented at the 46th annual meeting of the European Association for the Study of the Liver, Berlin, Germany, March 30-April 3, 2011.
12. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85: 2485-2502.
13. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
14. Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury T, et al. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. HEPATOLOGY 2011; 54: 1956-1965.
15. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54: 3641-3650.
16. Fridell RA, Wang C, Sun J-H, O'Boyle DR, II, Peter Nower, Valera L, et al. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations. HEPATOLOGY 2011; 54: 1924-1935.
17. Lemm JA, Liu M, Rose RE, Fridel DR, O'Boyle DR, Colonno HR, Gao M. Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology 2005; 48: 183-191.
18. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77: 51-59.
19. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. Distinct function of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011; 85: 7312-7320.
20. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005; 435: 374-379.
21. Love RA, Brodsky O, Hichey MJ, Wells PA, Cronin CN. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 2009; 83: 4395-4403.
22. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997; 277: 570-574.
23. Lohmann V, Korner F, Koch JO, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.